McKesson Co. (MCK) EVP Lori A. Schechter Sells 2,766 Shares

McKesson Co. (NYSE:MCK) EVP Lori A. Schechter sold 2,766 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $133.59, for a total value of $369,509.94. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of McKesson stock opened at $125.61 on Thursday. The firm has a market capitalization of $23.75 billion, a P/E ratio of 9.26, a PEG ratio of 1.27 and a beta of 1.23. The company has a quick ratio of 0.58, a current ratio of 1.02 and a debt-to-equity ratio of 0.88. McKesson Co. has a fifty-two week low of $106.11 and a fifty-two week high of $151.86.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, May 8th. The company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.66 by $0.03. McKesson had a net margin of 0.02% and a return on equity of 29.02%. The business had revenue of $52.43 billion during the quarter, compared to the consensus estimate of $53.14 billion. During the same quarter in the prior year, the firm earned $3.49 EPS. The business’s revenue was up 1.6% on a year-over-year basis. On average, sell-side analysts forecast that McKesson Co. will post 14.15 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date of this dividend is Friday, May 31st. McKesson’s dividend payout ratio (DPR) is currently 11.50%.

Several large investors have recently modified their holdings of the company. Proficio Capital Partners LLC boosted its stake in McKesson by 161.2% in the fourth quarter. Proficio Capital Partners LLC now owns 222 shares of the company’s stock valued at $25,000 after acquiring an additional 137 shares in the last quarter. Bedel Financial Consulting Inc. raised its holdings in shares of McKesson by 165.2% during the fourth quarter. Bedel Financial Consulting Inc. now owns 236 shares of the company’s stock worth $26,000 after purchasing an additional 147 shares during the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in shares of McKesson during the first quarter worth $27,000. Smart Portfolios LLC purchased a new position in shares of McKesson during the first quarter worth $35,000. Finally, Investors Research Corp purchased a new position in McKesson in the first quarter valued at $36,000. 86.35% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently weighed in on MCK. Zacks Investment Research downgraded McKesson from a “hold” rating to a “sell” rating in a research note on Thursday, May 2nd. ValuEngine raised McKesson from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 8th. Barclays reissued a “hold” rating and set a $130.00 price objective on shares of McKesson in a report on Friday, February 1st. Deutsche Bank raised McKesson from a “sell” rating to a “hold” rating and set a $175.00 price objective for the company in a report on Friday, January 25th. Finally, UBS Group assumed coverage on McKesson in a report on Thursday, January 17th. They issued a “neutral” rating and a $134.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $134.90.

TRADEMARK VIOLATION WARNING: This piece was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at

About McKesson

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Recommended Story: What is net income?

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with's FREE daily email newsletter.